Neuro-oncology practice最新文献

{"title":"Imaging progression after radiotherapy for IDH mutant low-grade glioma: Sometimes it is best to stay calm and stay the course.","authors":"Solmaz Sahebjam, Lawrence Kleinberg","doi":"10.1093/nop/npaf055","DOIUrl":"10.1093/nop/npaf055","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"543-544"},"PeriodicalIF":2.5,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Just a bit outside: An attempt to improve overlooked symptoms and how this may be accomplished.","authors":"Patrick Regis, Megan Kranz, Robert Cavaliere","doi":"10.1093/nop/npaf054","DOIUrl":"10.1093/nop/npaf054","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"541-542"},"PeriodicalIF":2.5,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measures of physical functioning in adults with brain tumor associated with functional outcomes: A scoping review.","authors":"Tara S Davis, Emory Hsieh, Bennett A McIver, Kaitlynn Slattery, McKenzie C Kauss, Diane Cooper, Vivian A Guedes, Terri S Armstrong, Michelle L Wright","doi":"10.1093/nop/npaf036","DOIUrl":"10.1093/nop/npaf036","url":null,"abstract":"<p><p>Neuro-oncology researchers and clinicians rely mostly on subjective measures to evaluate physical functioning (PF) and predict survival in primary brain tumor (PBT) patients. Exploring alternative clinical outcome assessment (COA) measures may identify more objective measures that better quantify PF in PBT patients. A scoping review was conducted to identify studies related to PF measures used in PBT patients. Using the PRISMA-SCRA guideline 3 databases (PubMed, Web of Science, and Cochrane Library) were searched on January 25, 2024. Reviewers performed an independent review of titles, abstracts, and full text using covidence systematic review software and a standardized Microsoft Excel form for extracting data. 1093 publications were identified; 49 studies met eligibility criteria. Studies used a variety of PF measures evaluated at different time points, ranging from preintervention to 3 years or more postintervention. 39 PF COA measures were identified. Of the 39, 3 clinician-reported measures (ClinRO) [KPS, ECOG, and FIM] are validated for PBT. Many measures found are standardized for other neurological diseases including performance (PerfO) and patient-reported outcome (PRO) measures. Validation of additional COA types (PerfO and PRO) that are complementary to the ClinRO measures already validated for the PBT population should be established. Measures of interest should include the evaluation of walking due to its clinical relevance and indication for overall PF.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"571-584"},"PeriodicalIF":2.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating liquid biopsy biomarkers for early detection of brain metastasis: A systematic review.","authors":"Jinyue Yu, Craig Paterson, Phillippa Davies, Jennifer C Palmer, Julian P T Higgins, Kathreena M Kurian","doi":"10.1093/nop/npaf032","DOIUrl":"10.1093/nop/npaf032","url":null,"abstract":"<p><strong>Background: </strong>Brain metastases (BMs) are the most common intracranial malignancy in adults, contributing significantly to cancer-related morbidity and mortality. Early detection is critical for optimizing treatment and improving survival. This systematic review evaluates the diagnostic potential of liquid biopsy biomarkers for detecting BM from lung, breast, and other cancers.</p><p><strong>Methods: </strong>A comprehensive search was conducted in MEDLINE, Embase, and BIOSIS databases using keywords related to liquid biopsy, biomarkers, and BMs. Data on participant characteristics, diagnostic reference standards, types of biomarkers, primary cancer origins, and diagnostic outcomes were independently extracted. Diagnostic performance was evaluated using sensitivity, specificity, and area under the curve (AUC). Risk of bias was assessed using the QUADAS-2 tool.</p><p><strong>Results: </strong>Thirty-one studies involving 5676 participants were included, assessing biomarkers such as cfDNA, miRNAs, proteins (eg, neurofilament light [NfL], glial fibrillary acidic protein [GFAP], S100B), metabolomic profiles, and multi-marker models. NfL and GFAP emerged as the most promising biomarkers, demonstrating moderate to strong diagnostic performance across multiple cancer types. Multi-marker models combining NfL and GFAP achieved sensitivity and specificity exceeding 90%. S100B showed variable performance due to differences in study designs and thresholds. Emerging biomarkers like cfDNA and metabolomic profiles showed potential but require further validation.</p><p><strong>Conclusions: </strong>Liquid biopsy biomarkers, particularly NfL and GFAP, hold promise for non-invasive BM detection. Clinical utility may be in the initial cancer workup for localized tumor to prompt brain imaging. Future research is required to validate biomarkers in larger, diverse populations across different cancer types.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"600-617"},"PeriodicalIF":2.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial burden after brain tumor diagnosis: The cost of disease for patients and caregivers.","authors":"Caroline Hertler","doi":"10.1093/nop/npaf010","DOIUrl":"10.1093/nop/npaf010","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 2","pages":"181-182"},"PeriodicalIF":2.4,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2021 WHO classification of tumors of the central nervous system: Responding to the challenge in low- and middle-income countries.","authors":"Michael J Sullivan, David D Eisenstat","doi":"10.1093/nop/npaf028","DOIUrl":"10.1093/nop/npaf028","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 3","pages":"355-356"},"PeriodicalIF":2.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Language testing in awake craniotomy for brain tumor resection: A survey of current perioperative practice in the United Kingdom.","authors":"Sonia Mariotti, Neil U Barua, T R Williamson, Hajira Mumtaz, Kris Kinsey, Anna E Piasecki","doi":"10.1093/nop/npaf027","DOIUrl":"10.1093/nop/npaf027","url":null,"abstract":"<p><strong>Background: </strong>Language testing and mapping procedures are considered the gold standard for safe tumor resection and preservation of language and communication in patients with tumors located in an area eloquent for language, especially in the presence of low-grade gliomas. However, the current status of language testing in awake craniotomy in the United Kingdom is unknown. The main aim of this study was to describe the language testing practices in awake brain surgery across the United Kingdom.</p><p><strong>Methods: </strong>An online survey was addressed to medical practitioners working with brain tumor patients during the phases of language testing. Questions inquired about the tests and approaches for language testing before, during, and after the surgery. The survey also explored the management of bilingual (for the sake of simplicity, the term bilingual is used throughout the article to refer to patients who speak 2 or more languages) brain tumor patients and gathered personal perspectives from clinicians.</p><p><strong>Results: </strong>Responses were obtained from 37 clinicians. Speech and language therapists and neuropsychologists administered language tests to patients, and those with sufficient language skills for completing intraoperative tests were eligible for awake mapping. A combination of standardized language batteries and homemade tasks were used for language testing, leading to variability in testing practices across institutions. For language mapping, the most popular tasks were picture naming, sentence completion, and repetition. Object and action naming were used across both the monolingual and bilingual patient groups. The timing of postoperative assessments varied according to patient needs and clinician availability. Bilingual patients were evaluated with interpreters and limited materials, compared to monolinguals.</p><p><strong>Conclusions: </strong>The provision of awake craniotomy language testing presents differences across UK-based institutions. Responders advocate for more comprehensive, updated, and inclusive materials to facilitate language testing in modern patient cohorts spanning a wide range of linguistic skills and foreign languages.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"654-662"},"PeriodicalIF":2.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focusing attention on brain metastasis: Hot issues.","authors":"Roberta Rudà, Riccardo Soffietti","doi":"10.1093/nop/npaf025","DOIUrl":"10.1093/nop/npaf025","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 3","pages":"353-354"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>It's like living with a ticking time bomb</i>-A qualitative study about patients' and their families' experiences related to the recurrence of a high-grade glioma.","authors":"Helle Sorensen von Essen, Karina Dahl Steffensen, Frantz Rom Poulsen, Karin Piil","doi":"10.1093/nop/npaf026","DOIUrl":"10.1093/nop/npaf026","url":null,"abstract":"<p><strong>Background: </strong>High-grade gliomas (HGG) are the most aggressive and infiltrative subtype of primary brain tumors. The average survival rate from diagnosis is less than 2 years, and all patients eventually experience a recurrence. However, our understanding of patients' and their families' experiences and coping mechanisms concerning the inevitable recurrence remains limited. This qualitative study explored how patients with HGG and their close family members experience and cope with their fear of recurrence and the diagnosis of HGG recurrence.</p><p><strong>Methods: </strong>Semistructured individual interviews were conducted with patients with HGG and their family members. Following an inductive phenomenological hermeneutical approach, the interviews were coded, and the findings were divided into themes.</p><p><strong>Results: </strong>The study included 15 patients and 14 family members between the ages of 22 and 79. We identified 3 interrelated themes illustrating the complex experiences related to an HGG recurrence. Theme I, <i>Navigating the fear of recurrence</i>, describes experiences and coping mechanisms during the disease trajectory. Theme II, <i>Facing reality and preparing for death</i> and Theme III, <i>Redefining hope in the era of recurrence</i>, illustrate experiences related to the recurrence diagnosis and redefinition of hopes for the future.</p><p><strong>Conclusion: </strong>Fear of recurrence is prominent in patients with HGG and their families, and the recurrence diagnosis triggers thoughts about death and the end-of-life phase. This new knowledge can be used to tailor support to patients and family members during the disease trajectory and personalize advance care planning consultations.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"723-731"},"PeriodicalIF":2.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A volumetric analysis of timing and duration of T2/FLAIR changes on MRI following radiation therapy in patients with low-grade IDH-mutant glioma.","authors":"Isabella Sutherland, Adam Ulano, Alissa A Thomas","doi":"10.1093/nop/npaf024","DOIUrl":"10.1093/nop/npaf024","url":null,"abstract":"<p><strong>Background: </strong>Patients with IDH-mutant low-grade glioma (LGG) can achieve many years of survival with radiation (RT) and chemotherapy. There is a risk of overtreatment and negative treatment side effects if these patients are unnecessarily retreated due to perceived tumor progression in the absence of true tumor regrowth. A better understanding of volumetric postradiation FLAIR changes will help with the clinical interpretation of disease progression/treatment effect and will help guide management decisions. We conducted this research to characterize the changes in MRI FLAIR hyperintensity that occur in LGG patients following RT, to better understand the radiation-treatment effects or \"pseudoprogression\" that occurs in the absence of true tumor regrowth.</p><p><strong>Methods: </strong>Serial MRI scans of patients with LGG were reviewed, including pre-RT and for 2.5 years post-RT. Segmentation for volumetric analysis was performed with manual supervision using ITK-SNAP (open-source segmentation software). Descriptive statistics are reported.</p><p><strong>Results: </strong>Sixteen patients with histologic grade 2 gliomas were included. 159 MRI scans were segmented using ITK-SNAP (median 9.5 MRIs/patient). Nine of 16 MRIs showed decreasing FLAIR volume immediately post-RT, while 7/16 showed increasing FLAIR volume. After the initial post-RT MRI, 12/16 patients had MRIs with an increase in FLAIR volume sometime during the first year. The FLAIR volume stabilized or decreased a median of 18.4 months and a mean of 15.0 months post-RT.</p><p><strong>Conclusions: </strong>FLAIR hyperintensity changes on MRI are highly variable in the first 1.5 years post-RT in low-grade glioma, but after 1.5 years, FLAIR volumes stabilize and decrease, likely indicating the inflection point where post-RT pseudoprogression stabilizes.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"631-636"},"PeriodicalIF":2.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}